|View printer-friendly version|
|St. Jude Medical Announces European Approval and Launch of the EnligHTN Renal Denervation System for Treatment of Hypertension|
Decades of experience in ablation technologies used to develop the industry’s first multi-electrode technology for renal denervation
Hypertension is a root cause of a variety of life-threatening health
problems, including heart disease, stroke, and kidney failure. It
impacts more than 1 billion people globally at an estimated cost of
“In my experience, the EnligHTN renal denervation system has been
successful in reducing blood pressure in patients with resistant
hypertension,” said Prof.
Using the EnligHTN system, an ablation catheter delivers radiofrequency (RF) energy to create lesions (tiny scars) along the renal sympathetic nerves – a network of nerves that help to regulate pressure; the intentional disruption of the nerve supply has been clinically found to decrease systolic blood pressure. This is important because the risk of cardiovascular death is cut in half with every 20 point decrease in systolic blood pressure.
“St. Jude Medical is focused on improving patient care while reducing
the economic burden of epidemic diseases, and our groundbreaking
EnligHTN renal denervation system is a great example of that focus,”
The system is the industry’s first multi-electrode ablation technology for renal denervation. With the unique basket design, each placement of the ablation catheter allows a consistent and predictable pattern of four ablations in 90-second intervals. Compared to single electrode ablations, the multi-electrode EnligHTN system has the potential to improve consistency and procedural reliability, save time as well as result in workflow and cost efficiencies. Additionally, the minimal catheter repositioning may result in a reduction of contrast and fluoroscopic (x-ray) exposure.
The technology includes a guiding catheter, ablation catheter and ablation generator. The generator uses a proprietary, temperature-controlled algorithm to deliver effective therapy.
Renal Denervation at EuroPCR
Data from the EnligHTN I (ARSENAL) trial, a prospective, multi-center
study for the St. Jude Medical EnligHTN renal denervation system, will
be presented during the session Novel Approaches to Renal
Denervation: Preclinical and First-In-Man Studies on
Attendees can visit
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the
St. Jude Medical, Inc.